Lys-MDA

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.^[2][3][4][5] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.^[6] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.^[1]

Lys-MDA

Clinical data
Routes of administration	Oral[1]
Drug class	Serotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT2 receptor agonist; Entactogen; Empathogen; Serotonergic psychedelic; Hallucinogen; Stimulant
ATC code	None
Pharmacokinetic data
Metabolites	MDA[1]
Identifiers
IUPAC name (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number	1391487-26-5
Chemical and physical data
Formula	C16H25N3O3
Molar mass	307.394 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN

See also

• Substituted methylenedioxyphenethylamine
• Lisdexamfetamine
• Serdexmethylphenidate
• N-t-BOC-MDMA